Dulaglutide Approved for Type 2 Diabetes

Once-weekly subcutaneous injection of Trulicity (dulaglutide), a glucagon-like peptide-1 receptor agonist.
Once-weekly subcutaneous injection of Trulicity (dulaglutide), a glucagon-like peptide-1 receptor agonist.

Trulicity (dulaglutide), a once-weekly subcutaneous injection, has been approved by the U.S. Food and Drug Administration to improve glycemic control in adults with type 2 diabetes along with diet and exercise.

Trulicity is a glucagon-like peptide-1 receptor agonist. Trulicity's safety and effectiveness were evaluated in clinical trials involving 3,342 people with type 2 diabetes. The drug has been studied as a stand-alone treatment and in combination with other therapies, the agency said.

Trulicity's label has a boxed warning that some lab rodents given the drug developed a certain type of thyroid tumor called medullary thyroid carcinoma (MTC). While it's not known if the drug could cause the same problem in people, those at risk of developing MTC shouldn't be given the drug, the FDA said. The drug also should not be given to people with type 1 diabetes, those who have increased blood or urine ketones, or to people with severe gastrointestinal problems, the agency warned.

The FDA said it is requiring additional studies of the drug to further evaluate its use in children, any cardiovascular risks, and its potential to cause MTC.

Trulicity is produced by Eli Lilly, based in Indianapolis.

Loading links....
You must be a registered member of Renal and Urology News to post a comment.